EUVIMEDEUVIMED entdecken
Crossref

Blocking the Signal: Interrupting Inflammatory Signaling in Atopic Dermatitis

Youngjoo Kim

QUBES · 23.08.2026

DOI: 10.25334/2kn6-fm79 ↗

Kurz gefasst

Fachartikel in der Zeitschrift QUBES, erschienen am 23.08.2026. Verfasst von Youngjoo Kim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Learning Objectives Explain how monoclonal antibodies can be used as therapeutic agents to treat disease. Describe the molecular mechanism by which an antibody inhibitor disrupts interleukin signaling pathways. Analyze the three-dimensional structures of IL-4 bound to the IL-4 receptor and dupilumab bound to the IL-4 receptor. Identify and compare the intermolecular forces involved in IL-4–IL-4 receptor interactions versus dupilumab–IL-4 receptor interactions.

Schlagwörter

atopic dermatitisdupilumabIL-4 receptorIL-4monoclonal antibodiesantibody inhibitorsinflammatory signalingprotein-protein interactionprotein structureintermolecular interactions

Zitieren

APA

Kim, Y. (2026). Blocking the Signal: Interrupting Inflammatory Signaling in Atopic Dermatitis. QUBES. https://doi.org/10.25334/2kn6-fm79

Vancouver

Kim Y. Blocking the Signal: Interrupting Inflammatory Signaling in Atopic Dermatitis. QUBES. 2026. doi:10.25334/2kn6-fm79

BibTeX
@article{Kim2026,
  author = {Kim, Youngjoo},
  title = {Blocking the Signal: Interrupting Inflammatory Signaling in Atopic Dermatitis},
  journal = {QUBES},
  year = {2026},
  doi = {10.25334/2kn6-fm79}
}
Kostenlos starten →